Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peresolimab in moderately to severely active rheumatoid arthritis
NCT04634253Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of peresolimab in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Jan 2021; status: completed.
02
Drugs
peresolimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04634253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634253.